Michael T. Lotze

University of Pittsburgh — United States

Immunology and Microbiology · Life Sciences

134h-index81.6kcitations895works5.72yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(231), Cancer Immunotherapy and Biomarkers(157), Immune Cell Function and Interaction(155), CAR-T cell therapy research(115), Autophagy in Disease and Therapy(107)

Publications884 total

Definitive SBRT in unresectable pancreatic cancer: Long-term outcomes with moderate vs high dose approaches.

Journal of Clinical Oncology·2026

Stereotactic body radiotherapy for resectable pancreatic ductal adenocarcinoma in patients unfit for surgical resection: A single-institution experience.

Journal of Clinical Oncology·2026

Rethinking dogma: Association between radiation dose and pathologic outcomes or survival in patients receiving neoadjuvant radiotherapy for pancreatic cancer.

Journal of Clinical Oncology·2026

Pancreatic Cancer Organoids Recapitulate Chemotherapy Response and Identify a Potent Cytotoxic T-Cell Population

Clinical Cancer Research·2025

Supplementary Table 1 - Gene Expression from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

2025Open Access

Supp. Figure 6 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

2025Open Access

Supp. Figure 4 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

2025Open Access

Supp. Figure 3 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

2025Open Access

Supp. Figure 5 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

2025Open Access

Supp. Figure 1 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

2025Open Access

Supplementary Figure Legends from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

2025Open Access

Supp. Figure 2 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

2025Open Access

1116 Framework for modeling immunostimulatory versus immunosuppressive effects of radiotherapy on antitumor immunity

Regular and Young Investigator Award Abstracts·2025Open Access

The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee

2 cited

Journal for ImmunoTherapy of Cancer·2025· 2 citedOpen Access

Second signals for cancer immunotherapy

1 cited

Journal for ImmunoTherapy of Cancer·2025· 1 citedOpen Access

Zelig Eshhar (1941–2025): a tribute for a life for immunotherapy

Journal for ImmunoTherapy of Cancer·2025Open Access

PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism

1 cited

Developmental Cell·2025· 1 cited

Correction to: The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival

Cell Death and Differentiation·2025

Correction: HMGB1 release and redox regulates autophagy and apoptosis in cancer cells

Oncogene·2025Open Access

Lessons Learned About Acute and Late Toxicity After Two Decades of Experience With Pancreatic SBRT

Journal of the National Comprehensive Cancer Network·2025Open Access

page 1 of 45Next →

Frequent Co-authors

Daolin Tang(19), Herbert J. Zeh(16), Rui Kang(16), Steven A. Rosenberg(12), Claudia A. Seipp(9), Timothy R. Billiar(9), Guido Kroemer(6), W. Marston Linehan(4), Donald E. White(4), Kevin J. Tracey(4), Herbert J. Zeh(4), Paul Aebersold(4), Suzanne L. Topalian(4), Wen‐Chi Hou(4), Yangchun Xie(4), Alfred E. Chang(3), Colleen Simpson(3), Stephen E. Ettinghausen(3), Yvedt L. Matory(3), Xinxin Song(3)